Enlivex Therapeutics Stock Forum

$Enlivex Therapeutics (ENLV.US)$
Can Enlivex's Osteoarthritis Treatment Disrupt a Multi-Billion Dollar Market? 6-Month Data Impresses

$Enlivex Therapeutics (ENLV.US)$ Enlivex Announces Interim Six-month Efficacy Data From Phase I Stage Of Its Randomized, Multi-Country Phase I/II Allocetra Trial In Patients With Moderate To Severe Knee Osteoarthritis.
Benzinga· 1 min ago
Statistically significant 47.0% average reduction of reported pain (P=0.0001) compared to average pain level at baseline46% improvement in joint function and 40% improvement in joint stiffness83% of the patients were still considered as responders to treat...

$Enlivex Therapeutics (ENLV.US)$
Enlivex Takes Legal Action Against Market Manipulation as Stock Trading Continues Uninterrupted

$Enlivex Therapeutics (ENLV.US)$ Enlivex Issues Urgent Statement on Fraudulent News Dissemination
2 MINUTES AGO, 6:20 AM EST
VIA GLOBENEWSWIRE
Ness-Ziona, Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq and TASE: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company, alerts investors and the public that a completely false and misleading report regarding the Company was intentionally published this morning by the website Tipranks.com claiming ...

$Enlivex Therapeutics (ENLV.US)$
Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Friday, 10th January at 9:00 am
ORLANDO, FL / ACCESSWIRE / January 10, 2025 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (NASDAQ: ENLV) and bioAffinity Technologies, Inc. (NASDAQ: BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, January 11, at 7 p.m....

$Enlivex Therapeutics (ENLV.US)$
Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis
Wednesday, 11th December at 8:30 am
Ness-Ziona, Israel, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ: ENLV, the "Company")), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Israeli Ministry of Health authorized the initiation of an investigator-initiated Phase ...

$Enlivex Therapeutics (ENLV.US)$ Benzinga· just
Enlivex Therapeutics Receives Regulatory Authorization From Israeli Ministry Of Health For Initiation Of Phase I Trial Evaluating Allocetra In Patients With TMJ Osteoarthritis

$Enlivex Therapeutics (ENLV.US)$
Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis
Tuesday, 3rd December at 8:30 am
Nes-Ziona, Israel, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ: ENLV, the "Company")), a clinical-stage macrophage reprogramming immunotherapy company, today announced positive interim efficacy data from the Phase I stage of its randomized, multi-country Phase I/II Allocetra™ tri...

$Enlivex Therapeutics (ENLV.US)$
Enlivex Adopts Bitcoin Treasury Reserve Strategy